HK Stock MarketDetailed Quotes
02500 VENUS MEDTECH-B
- 5.620
- 0.0000.00%
Market Closed Apr 19 16:08 CST
2.48BMarket Cap-3115P/E (TTM)
0.000High0.000Low0Volume5.620Open5.620Pre Close0.00Turnover0.00%Turnover RatioLossP/E (Static)441.01MShares11.50052wk High0.77P/B2.48BFloat Cap3.74052wk Low--Dividend TTM441.01MShs Float97.000Historical High--Dividend LFY0.00%Amplitude3.740Historical Low--Avg Price500Lot Size--Div YieldTTM--Div Yield LFY
VENUS MEDTECH-B Key Stats
All
YOY
| (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | (FY)Dec 31, 2020 | (Q6)Jun 30, 2020 | (FY)Dec 31, 2019 | (FY)Dec 31, 2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 20.89%491.37M | 21.74%255.61M | -2.26%406.46M | -12.25%209.97M | 50.65%415.86M | 134.46%239.27M | 18.34%276.05M | --102.05M | 102.23%233.27M | 535.04%115.35M |
| Operating income | 20.89%491.37M | 21.74%255.61M | -2.26%406.46M | -12.25%209.97M | 50.65%415.86M | 134.46%239.27M | 18.34%276.05M | 102.05M | 102.23%233.27M | 535.04%115.35M |
| Cost of sales | -10.50%-102.17M | -18.72%-54.36M | -1.03%-92.46M | 10.53%-45.79M | -87.66%-91.52M | -201.74%-51.18M | -26.32%-48.77M | ---16.96M | -135.87%-38.61M | -431.95%-16.37M |
| Operating expenses | -10.50%-102.17M | -18.72%-54.36M | -1.03%-92.46M | 10.53%-45.79M | -87.66%-91.52M | -201.74%-51.18M | -26.32%-48.77M | -16.96M | -135.87%-38.61M | -431.95%-16.37M |
| Gross profit | 23.95%389.21M | 22.58%201.25M | -3.19%314M | -12.71%164.18M | 42.71%324.34M | 121.05%188.09M | 16.75%227.28M | 85.09M | 96.67%194.67M | 556.06%98.98M |
| Selling expenses | -15.40%-300.48M | -28.01%-157.91M | -20.51%-260.38M | -24.54%-123.36M | -60.56%-216.07M | -109.79%-99.05M | -8.03%-134.57M | ---47.22M | -86.30%-124.57M | -86.14%-66.87M |
| Administrative expenses | 16.46%-160.55M | -42.28%-77.89M | -49.46%-192.18M | -22.22%-54.75M | -23.56%-128.59M | -14.40%-44.79M | 47.34%-104.06M | ---39.16M | 11.73%-197.61M | -997.75%-223.86M |
| Research and development expenses | 0.48%-524.92M | -33.77%-294.72M | -104.17%-527.45M | -111.18%-220.32M | -54.46%-258.34M | -54.32%-104.33M | 16.60%-167.25M | ---67.61M | -91.39%-200.53M | 10.72%-104.77M |
| Impairment and provision | 110.06%2.21M | -168.60%-9.66M | -589.86%-21.97M | -12.52%-3.6M | -6,470.00%-3.19M | -236.67%-3.2M | 102.30%50K | ---949K | -29.75%-2.17M | -407.27%-1.67M |
| -Other impairment is provision | 110.06%2.21M | -168.60%-9.66M | -589.86%-21.97M | -12.52%-3.6M | -6,470.00%-3.19M | -236.67%-3.2M | 102.30%50K | ---949K | -29.75%-2.17M | -407.27%-1.67M |
| Operating interest expense | ---- | -69.48%-31.19M | ---- | -1,769.92%-18.4M | 54.34%-1.91M | 67.99%-984K | 80.97%-4.17M | ---3.07M | ---21.92M | ---- |
| Special items of operating profit | 79.79%-82.84M | -72.42%6.74M | -399.08%-409.79M | 152.61%24.43M | -2,128.83%-82.11M | -256.59%-46.43M | 87.47%-3.68M | --29.65M | -1,732.98%-29.41M | -39.56%1.8M |
| Operating profit | 38.30%-677.37M | -56.75%-363.38M | -200.07%-1.1B | -109.43%-231.81M | -96.25%-365.84M | -155.84%-110.69M | 51.14%-186.41M | -43.26M | -28.73%-381.54M | -90.07%-296.4M |
| Financing cost | -40.55%-62.72M | ---- | ---44.62M | ---- | ---- | ---- | ---- | ---- | ---- | -113.51%-3.22M |
| Share of profits of associates | -10.30%-10.87M | 51.38%-5.88M | 15.88%-9.85M | -85.42%-12.1M | -2,154.56%-11.71M | -2,361.51%-6.52M | --570K | ---265K | ---- | ---- |
| Share of profit from joint venture company | 62.98%-1.52M | 56.65%-1.08M | ---4.09M | ---2.5M | ---- | ---- | ---- | ---- | ---- | ---- |
| Earning before tax | 34.93%-752.46M | -50.30%-370.34M | -206.27%-1.16B | -110.22%-246.41M | -103.16%-377.56M | -169.27%-117.21M | 51.29%-185.84M | -43.53M | -27.34%-381.54M | -90.30%-299.62M |
| Tax | -81.68%6.28M | -38.79%4.12M | 456.76%34.3M | 168,550.00%6.74M | 107.09%6.16M | 55.56%-4K | 282.39%2.98M | ---9K | 186.64%778K | -79.60%-898K |
| After-tax profit from continuing operations | 33.50%-746.18M | -52.80%-366.22M | -202.12%-1.12B | -104.47%-239.67M | -103.09%-371.39M | -169.22%-117.22M | 51.97%-182.87M | -43.54M | -26.70%-380.77M | -90.26%-300.52M |
| Earning after tax | 33.50%-746.18M | -52.80%-366.22M | -202.12%-1.12B | -104.47%-239.67M | -103.09%-371.39M | -169.22%-117.22M | 51.97%-182.87M | -43.54M | -26.70%-380.77M | -90.26%-300.52M |
| Minority profit | 60.68%-25.3M | 59.67%-16.03M | -2,969.89%-64.34M | -857.01%-39.74M | 355.06%2.24M | -29,557.14%-4.15M | -1,992.86%-879K | ---14K | 56.70%-42K | 93.15%-97K |
| Profit attributable to shareholders | 31.84%-720.88M | -75.15%-350.19M | -183.08%-1.06B | -76.83%-199.93M | -105.31%-373.64M | -159.77%-113.06M | 52.20%-181.99M | -43.52M | -26.73%-380.72M | -91.92%-300.42M |
| Basic earnings per share | 31.82%-1.65 | -73.91%-0.8 | -184.71%-2.42 | -76.92%-0.46 | -88.89%-0.85 | -136.36%-0.26 | 63.11%-0.45 | -0.11 | -18.45%-1.22 | -53.73%-1.03 |
| Diluted earnings per share | 31.82%-1.65 | -73.91%-0.8 | -184.71%-2.42 | -76.92%-0.46 | -88.89%-0.85 | -136.36%-0.26 | 63.11%-0.45 | -0.11 | -18.45%-1.22 | -53.73%-1.03 |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS | IAS |
| Audit Opinions | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | Unqualified Opinion |
| Auditor | Zhonghui Certified Public Accountants | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | -- | Ernst & Young | Ernst & Young |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
Analysis
Price Target
No Data
Heat List
HK
Overall
Symbol
Latest Price
%Chg